Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: Budesonide Prophylaxis for Diarrhea in MM Patients Undergoing ASCT
NCT05405387Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- May 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EPI-EE in diarrhea (3 arms), sponsored by University of Utah. Primary endpoints: Proportion of patients with delayed engraftment and severe infection related complications at 18 days and Incidence of Grade 2 or higher diarrhea at 14 days. Started May 2023; status: recruiting.
02
Drugs
EPI-EE
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT05405387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405387.